NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Price Target & More

$18.83 +0.17 (+0.91 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$18.66
Today's Range$18.59 - $19.10
52-Week Range$11.88 - $30.71
Volume138,337 shs
Average Volume374,970 shs
Market Capitalization$429.35 million
P/E Ratio4.63
Dividend YieldN/A
Beta1.02

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Debt-to-Equity RatioN/A
Current Ratio31.95%
Quick Ratio31.95%

Price-To-Earnings

Trailing P/E Ratio4.63
Forward P/E Ratio-8.01
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.89 million
Price / Sales3.04
Cash Flow$4.3188 per share
Price / Cash4.36
Book Value$8.63 per share
Price / Book2.18

Profitability

EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Net Margins66.47%
Return on Equity-36.25%
Return on Assets-31.01%

Miscellaneous

Employees64
Outstanding Shares23,230,000

How to Become a New Pot Stock Millionaire

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals (NASDAQ:CNCE) posted its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.08. The biotechnology company had revenue of $0.01 million for the quarter, compared to analyst estimates of $8.11 million. Concert Pharmaceuticals had a negative return on equity of 36.25% and a net margin of 66.47%. View Concert Pharmaceuticals' Earnings History.

What price target have analysts set for CNCE?

5 brokerages have issued twelve-month price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $25.00 to $34.00. On average, they expect Concert Pharmaceuticals' stock price to reach $27.60 in the next year. View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We don’t see a read-through from today’s news to the ultimate outcome of the IPR challenge. Based on how Concert has defended its patents historically and the impressive track record on IP protection front, we think it is likely they can win this challenge. PTAB Proceedings. In April 2017, Incyte filed an Inter Partes Review Petition (IPR) against Concert seeking to invalidate Concert’s U.S. Patent No. 9,249,149. Following this, in October 2017, the PTAB denied Incyte’s petition to institute the IPR. Today, the PTAB is granting Incyte’s motion for reconsideration. Oral arguments between the parties will be made in December followed by a PTAB decision, expected in April 2019. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (4/10/2018)
  • 2. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (3/8/2018)

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 60)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 63)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 46)

Has Concert Pharmaceuticals been receiving favorable news coverage?

News stories about CNCE stock have been trending positive on Thursday, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.41 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $18.83.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $429.35 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  361
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Concert Pharmaceuticals (NASDAQ:CNCE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Concert Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.60, suggesting that the stock has a possible upside of 46.57%. The high price target for CNCE is $34.00 and the low price target for CNCE is $25.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.803.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.60$27.60$26.00$26.20
Price Target Upside: 46.57% upside24.77% upside29.04% upside59.56% upside

Concert Pharmaceuticals (NASDAQ:CNCE) Consensus Price Target History

Price Target History for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ:CNCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018MizuhoReiterated RatingBuy$27.00MediumView Rating Details
3/2/2018HC WainwrightReiterated RatingBuy -> Buy$21.00 -> $25.00HighView Rating Details
1/12/2018Stifel NicolausReiterated RatingBuy$27.00N/AView Rating Details
12/19/2017UBSSet Price TargetBuy$22.00 -> $34.00HighView Rating Details
6/12/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings History and Estimates Chart

Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.35 EPS
Next Year EPS Consensus Estimate: $-2.41 EPS

Concert Pharmaceuticals (NASDAQ CNCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018Q4 2017($0.18)($0.26)$8.11 million$0.01 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.54)($0.70)$0.02 million$0.02 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.58)$0.20 million$0.02 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
3/31/2014Q4 2013($4.64)$1.41 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Concert Pharmaceuticals (NASDAQ:CNCE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 72.65%
Insider Trading History for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018James V CassellaInsiderSell10,582$20.18$213,544.7630,000View SEC Filing  
2/1/2018Richard AldrichDirectorSell11,946$20.89$249,551.94286,975View SEC Filing  
1/29/2018Richard AldrichDirectorSell18,054$20.63$372,454.02286,975View SEC Filing  
1/26/2018Richard AldrichDirectorSell5,000$20.46$102,300.00286,975View SEC Filing  
1/24/2018Richard AldrichDirectorSell30,000$19.68$590,400.00286,975View SEC Filing  
1/22/2018Richard AldrichDirectorSell10,000$19.55$195,500.00286,975View SEC Filing  
1/19/2018Richard AldrichDirectorSell30,000$19.35$580,500.00286,975View SEC Filing  
1/16/2018Richard AldrichDirectorSell31,236$19.14$597,857.04286,975View SEC Filing  
12/19/2017Value Fund L P BiotechnologyInsiderSell1,282,856$26.65$34,188,112.40View SEC Filing  
12/4/2017Ronald W BarrettDirectorSell14,156$24.70$349,653.203,539View SEC Filing  
10/19/2017Value Fund L P BiotechnologyInsiderBuy331,916$15.84$5,257,549.44View SEC Filing  
9/14/2017Ryan LynchInsiderSell3,500$14.51$50,785.009,500View SEC Filing  
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.002,000View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50538,965View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.6425,004View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.0010,000View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Concert Pharmaceuticals (NASDAQ CNCE) News Headlines

Source:
DateHeadline
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor ConferencesConcert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
finance.yahoo.com - April 26 at 8:40 AM
Concert Pharmaceuticals (CNCE) Lowered to Hold at ValuEngineConcert Pharmaceuticals (CNCE) Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 25 at 12:14 PM
Concert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair lossConcert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair loss
seekingalpha.com - April 25 at 8:45 AM
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia AreataConcert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
finance.yahoo.com - April 25 at 8:45 AM
Research Report Identifies Signature Bank,...Research Report Identifies Signature Bank,...
www.benzinga.com - April 23 at 8:36 AM
Insider Selling: Concert Pharmaceuticals (CNCE) Insider Sells 10,582 Shares of StockInsider Selling: Concert Pharmaceuticals (CNCE) Insider Sells 10,582 Shares of Stock
www.americanbankingnews.com - April 19 at 7:35 PM
Concert Pharmaceuticals (CNCE) Given Consensus Recommendation of "Buy" by BrokeragesConcert Pharmaceuticals (CNCE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:40 PM
Concert Pharmaceuticals (CNCE) Stock Rating Lowered by BidaskClubConcert Pharmaceuticals (CNCE) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM
$20,000.00 in Sales Expected for Concert Pharmaceuticals (CNCE) This Quarter$20,000.00 in Sales Expected for Concert Pharmaceuticals (CNCE) This Quarter
www.americanbankingnews.com - April 18 at 4:32 AM
Concert Pharmaceuticals (CNCE) Expected to Post Earnings of -$0.61 Per ShareConcert Pharmaceuticals (CNCE) Expected to Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - April 16 at 3:22 AM
Concert Pharmaceuticals (CNCE) Stock Rating Reaffirmed by HC WainwrightConcert Pharmaceuticals (CNCE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 11 at 11:23 PM
Concert Pharmaceuticals (CNCE) Earns "Buy" Rating from MizuhoConcert Pharmaceuticals (CNCE) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - April 10 at 1:42 PM
Concert Pharmaceuticals (CNCE) Coverage Initiated at MizuhoConcert Pharmaceuticals (CNCE) Coverage Initiated at Mizuho
www.americanbankingnews.com - April 4 at 9:04 PM
Concert Pharmaceuticals (CNCE) Raised to Buy at ValuEngineConcert Pharmaceuticals (CNCE) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM
Concert Pharmaceuticals (CNCE) Cut to C at TheStreetConcert Pharmaceuticals (CNCE) Cut to C at TheStreet
www.americanbankingnews.com - April 3 at 10:36 AM
 Analysts Expect Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $20,000.00 Analysts Expect Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $20,000.00
www.americanbankingnews.com - April 1 at 4:38 AM
 Analysts Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.61 Earnings Per Share Analysts Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - March 30 at 9:04 AM
Concert Pharmaceuticals (CNCE) Lifted to "B-" at TheStreetConcert Pharmaceuticals (CNCE) Lifted to "B-" at TheStreet
www.americanbankingnews.com - March 28 at 8:14 PM
Concert Pharmaceuticals (CNCE) Downgraded by ValuEngine to SellConcert Pharmaceuticals (CNCE) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 28 at 12:58 PM
Concert Pharmaceuticals (CNCE) Lowered to Hold at BidaskClubConcert Pharmaceuticals (CNCE) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:21 AM
BidaskClub Lowers Concert Pharmaceuticals (CNCE) to HoldBidaskClub Lowers Concert Pharmaceuticals (CNCE) to Hold
www.americanbankingnews.com - March 28 at 12:34 AM
Concert Pharmaceuticals (CNCE) Upgraded to Hold at ValuEngineConcert Pharmaceuticals (CNCE) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM
Concert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from BrokeragesConcert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:32 PM
Edited Transcript of CNCE earnings conference call or presentation 1-Mar-18 1:30pm GMTEdited Transcript of CNCE earnings conference call or presentation 1-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:46 AM
Zacks: Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Post -$0.61 Earnings Per ShareZacks: Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Post -$0.61 Earnings Per Share
www.americanbankingnews.com - March 13 at 5:18 AM
Concert Pharmaceuticals (CNCE) Upgraded to "Buy" by MizuhoConcert Pharmaceuticals (CNCE) Upgraded to "Buy" by Mizuho
www.americanbankingnews.com - March 9 at 11:24 PM
Concert Pharmaceuticals (CNCE) Stock Rating Upgraded by Zacks Investment ResearchConcert Pharmaceuticals (CNCE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 8 at 8:48 PM
Concert Pharmaceuticals Present at Upcoming Investor ConferencesConcert Pharmaceuticals Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 8:44 AM
Senzar Asset Management LLC Has $7.15 Million Holdings in Concert Pharmaceuticals Inc (CNCE)Senzar Asset Management LLC Has $7.15 Million Holdings in Concert Pharmaceuticals Inc (CNCE)
www.americanbankingnews.com - March 5 at 3:44 PM
Concert Pharmaceuticals (CNCE) "Buy" Rating Reaffirmed at HC WainwrightConcert Pharmaceuticals' (CNCE) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 3 at 6:02 PM
292,010 Shares in Concert Pharmaceuticals Inc (CNCE) Acquired by Bogle Investment Management L P DE292,010 Shares in Concert Pharmaceuticals Inc (CNCE) Acquired by Bogle Investment Management L P DE
www.americanbankingnews.com - March 3 at 4:52 AM
Concert Pharmaceuticals (CNCE) Downgraded to "Sell" at Zacks Investment ResearchConcert Pharmaceuticals (CNCE) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 2 at 9:02 PM
EAM Investors LLC Purchases Shares of 74,232 Concert Pharmaceuticals Inc (CNCE)EAM Investors LLC Purchases Shares of 74,232 Concert Pharmaceuticals Inc (CNCE)
www.americanbankingnews.com - March 2 at 1:06 PM
Concert Pharmaceuticals (CNCE) Releases  Earnings Results, Misses Estimates By $0.08 EPSConcert Pharmaceuticals (CNCE) Releases Earnings Results, Misses Estimates By $0.08 EPS
www.americanbankingnews.com - March 2 at 11:39 AM
Concert Pharma (CNCE) Announces Advancement of Novel Drug Candidate in SchizophreniaConcert Pharma (CNCE) Announces Advancement of Novel Drug Candidate in Schizophrenia
www.streetinsider.com - March 2 at 8:46 AM
Concert Pharmaceuticals (CNCE) Stock Rating Reaffirmed by MizuhoConcert Pharmaceuticals (CNCE) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - March 1 at 6:44 PM
Citadel Advisors LLC Lowers Holdings in Concert Pharmaceuticals Inc (CNCE)Citadel Advisors LLC Lowers Holdings in Concert Pharmaceuticals Inc (CNCE)
www.americanbankingnews.com - March 1 at 8:58 AM
Concert Pharmaceuticals Reports Year Ended 2017 Financial ResultsConcert Pharmaceuticals Reports Year Ended 2017 Financial Results
finance.yahoo.com - March 1 at 8:39 AM
Concert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from AnalystsConcert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 28 at 5:50 PM
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in SchizophreniaConcert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
finance.yahoo.com - February 28 at 5:36 PM
Concert Pharmaceuticals Inc (CNCE) Shares Sold by Senvest Management LLCConcert Pharmaceuticals Inc (CNCE) Shares Sold by Senvest Management LLC
www.americanbankingnews.com - February 26 at 11:36 AM
$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter
www.americanbankingnews.com - February 26 at 10:48 AM
Concert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per ShareConcert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - February 24 at 5:14 AM
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
finance.yahoo.com - February 21 at 8:49 AM
Concert Pharmaceuticals (CNCE) Given Hold Rating at MizuhoConcert Pharmaceuticals (CNCE) Given Hold Rating at Mizuho
www.americanbankingnews.com - February 13 at 11:58 AM
Concert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment ResearchConcert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 12 at 9:00 PM
Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia AreataConcert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
finance.yahoo.com - February 12 at 9:34 AM
Concert Pharmaceuticals (CNCE) Lifted to "Buy" at BidaskClubConcert Pharmaceuticals (CNCE) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - February 11 at 8:54 AM
Zacks: Analysts Anticipate Concert Pharmaceuticals Inc (CNCE) Will Announce Quarterly Sales of $8.11 MillionZacks: Analysts Anticipate Concert Pharmaceuticals Inc (CNCE) Will Announce Quarterly Sales of $8.11 Million
www.americanbankingnews.com - February 9 at 5:44 AM
 Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.18 Earnings Per Share Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - February 7 at 5:10 AM

SEC Filings

Concert Pharmaceuticals (NASDAQ:CNCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Concert Pharmaceuticals (NASDAQ:CNCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Concert Pharmaceuticals (NASDAQ CNCE) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.